FDA Gives Fast Track Boost to Climb Bio’s Budoprutug for Primary Membranous Nephropathy
Climb Bio stock jumps after FDA fast-track for budoprutug, a new drug for rare kidney disease pMN.
/ 2 items
Climb Bio stock jumps after FDA fast-track for budoprutug, a new drug for rare kidney disease pMN.
Piper Sandler launches coverage of biotech Climb Bio with an Overweight rating and $23 price target, highlighting its promising pipeline and key catalysts expected in 2026.